Immune cells undergo non-inherited genetic changes that are associated with higher Alzheimer’s risk.
BrightFocus President and CEO Stacy Pagos Haller spoke with WebMD about the latest breakthroughs in macular degeneration research.
A new study asks the question: what if we could reverse the damage caused by Alzheimer’s disease-related proteins like tau? Learn more.
Newly released research portfolios highlight the 276 biomedical research projects funded by BrightFocus Foundation across 16 countries to defeat Alzheimer’s disease, macular degeneration, and glaucoma.
The anti-amyloid therapy will go off the market later this year.
The U.S. Food and Drug Administration has approved a new treatment for glaucoma, iDose® TR (travoprost intracameral implant, 75 mcg). iDose TR is a first-of-its kind treatment that is designed to provide up to three years of 24/7, continuous drug therapy directly inside the eye, helping people with glaucoma take control over the elevated eye pressure associated with this vision disease.
In a new BrightFocus-funded study, researchers found an association between alterations in circadian rest-activity rhythms and risk of frailty incidence in older adults.
BrightFocus Foundation’s Alzheimer’s Fast Track, an immersive workshop for early-career scientists, was held Nov. 8-10 in Washington, D.C. and convened 80 talented Alzheimer’s researchers from 19 U.S. states and six countries, including Japan, Spain, and Sweden.
To achieve true health equity, we must ensure that all populations have equitable access to clinical trials and the benefits of medical research. With the right mix of resources, dedication, compassion, patience, and time, we can positively impact communities nationwide, write BrightFocus President and CEO Stacy Pagos Haller and board member Tonya M. Matthews, PhD, in a new op-ed.
In a first of its kind study, BrightFocus-funded researchers have identified a possible new way to improve drugs to treat glaucoma by studying a tiny part of the eye’s drainage system that plays a major role in eye pressure.